[{"indications": "Indications\u00a0\n(From 8.1.1 Alkylating drugs: British National Formulary)\nMelphalan is licensed for the treatment of multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities. Interstitial pneumonitis and life-threatening pulmonary fibrosis are rarely associated with melphalan.", "name": "MELPHALAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.1 Alkylating drugs", "MELPHALAN"], "cautions": "Cautions\u00a0see section 8.1 and notes above; avoid in acute porphyria (but see section 9.8.2); interactions: Appendix 1\r\n(melphalan)", "side-effects": "Side-effects\u00a0see section 8.1 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4694.htm", "doses": ["By mouth, multiple myeloma, dose\r\nmay vary according to regimen; typical dose 150\u00a0micrograms/kg daily\r\nfor 4 days, repeated every 6 weeks", "Polycythaemia vera, initially, 6\u201310\u00a0mg daily reduced after 5\u20137\r\ndays to 2\u20134\u00a0mg daily until satisfactory response then further reduce\r\nto 2\u20136\u00a0mg per week", "By intravenous injection or  infusion or by regional arterial\r\nperfusion, consult product literature"], "pregnancy": "Pregnancy\u00a0avoid (manufacturer advises adequate contraception\r\nduring treatment in men or women); see also Pregnancy and Reproductive\r\nFunction"}]